Salivary Duct Carcinoma: Symptoms, Diagnosis, & Treatment

Salivary duct carcinoma (SDC) is a rare, aggressive cancer that arises in the salivary glands and accounts for a small fraction of all salivary gland tumors. It overwhelmingly affects men in their sixties and tends to present as a fast-growing mass near the jaw or ear. What makes SDC unusual among head and neck cancers is how closely it resembles breast cancer under the microscope, a resemblance that has reshaped how oncologists treat it. The borrowing of breast cancer therapies, particularly those targeting hormone receptors and HER2, has opened doors that did not exist a generation ago.

What Salivary Duct Carcinoma Looks Like When It First Appears

The most common first sign is a painless lump that grows quickly, usually in the parotid gland, which sits just in front of and below the ear. Roughly four out of five SDC tumors originate in the parotid, with the submandibular gland under the jaw being the next most frequent site.¹ Because the parotid gland is threaded with branches of the facial nerve, a tumor growing there can press on or invade those nerve branches. When that happens, you may notice weakness or drooping on one side of the face, difficulty closing one eye, or an asymmetric smile.²

Some patients experience pain in the face or jaw, though many do not until the disease is advanced. Because SDC is prone to early spread, symptoms from distant metastases can occasionally be the first clue that something is wrong. One case report documented a patient whose initial complaints were difficulty speaking, vision changes, and weakness in multiple cranial nerves, all caused by intracranial spread from a submandibular tumor.³ That scenario is unusual, but it underscores how quickly SDC can move beyond the gland where it started.

Who Gets It

SDC is predominantly a disease of older men. Across multiple institutional reviews, the average age at diagnosis falls between 62 and 66, and men outnumber women by roughly two to one or more.¹⁴ Women can develop SDC, but the strong male predominance likely relates to the tumor’s high rate of androgen receptor expression, a feature discussed below.

As for environmental causes, the evidence is thin and mostly indirect. An older epidemiologic study found that prior radiation treatment to the head or neck was associated with increased risk for salivary gland cancers generally, along with a history of extensive dental X-rays, though these associations were strongest for exposures before the mid-1950s, when radiation doses were far higher than modern standards.⁵ No specific lifestyle or occupational exposure has been firmly linked to SDC in particular. For most patients, the reason the cancer developed remains unknown.

A subset of SDC cases arise from a pre-existing benign tumor called a pleomorphic adenoma, a common, slow-growing salivary gland lump that many people carry for years or decades. When a pleomorphic adenoma undergoes malignant transformation, the resulting cancer is called carcinoma ex pleomorphic adenoma, and SDC is one of its most frequent forms. This means that a longstanding salivary gland mass that suddenly starts growing faster deserves prompt evaluation.

How SDC Is Diagnosed

The workup typically starts with imaging, often an MRI or CT scan of the head and neck. These scans help define the tumor’s size, its relationship to surrounding structures like the facial nerve and nearby bones, and whether lymph nodes in the neck are involved. In one study of 20 SDC patients, imaging-based staging agreed with the final pathologic staging in about four out of five cases.⁶

A tissue sample is needed to confirm the diagnosis, and fine-needle aspiration (FNA) is usually the first step. A needle is inserted into the mass to withdraw cells for microscopic examination. FNA is reliable for determining that a salivary tumor is malignant: in a review of 70 FNA cases, about 86% were correctly classified as malignant or suspicious for malignancy. The catch is that identifying the exact type of salivary cancer from needle aspirates alone is harder, because several high-grade salivary tumors can look similar on cytology.⁷ A definitive SDC diagnosis often comes after surgical removal, when pathologists can examine the whole tumor and run additional stains.

For patients with suspected or confirmed recurrence, PET/CT scans using a radioactive glucose tracer can detect disease that conventional CT or MRI misses. One study of recurrent salivary gland cancers found that PET/CT picked up additional sites of recurrence in about 18% of patients beyond what standard imaging showed.⁸ A newer imaging approach uses a tracer that targets PSMA, a protein found on many SDC cells, and early-phase trials suggest it can reveal bone and lymph node metastases that other scans miss.⁹

Why SDC Resembles Breast Cancer Under the Microscope

Under a microscope, SDC looks strikingly like invasive ductal carcinoma of the breast. Both cancers form irregular clusters of abnormal cells with duct-like structures, and pathologists sometimes struggle to tell them apart when a tumor shows up in an unusual location. One study comparing the two systematically found that their structural patterns and protein expression profiles overlap heavily, with some key exceptions: SDC almost never expresses estrogen receptor, whereas most breast ductal carcinomas do; and SDC is more likely to overexpress HER2.¹⁰ An even broader comparison of ductal cancers from the breast, skin, and salivary glands confirmed that distinguishing among them based on structure alone can be impossible without clinical context.¹¹

The practical importance of this resemblance goes beyond pathology trivia. Both tumor types share high rates of androgen receptor (AR) expression: over 90% in one comparative analysis, and about 75% in a genomic characterization of SDC specifically.¹² That same molecular study found that SDC’s gene-expression patterns closely resemble a breast cancer subtype called molecular apocrine breast cancer. The implication is significant: treatment strategies that work in breast cancer may generate useful hypotheses for SDC, and that cross-pollination has already yielded results.

The Molecular Landscape and Why It Matters for Treatment

Genomic sequencing has revealed that SDC tumors carry a high burden of mutations, many of which are potentially targetable with existing drugs. The most frequently altered gene is TP53, found mutated in roughly half to two-thirds of cases depending on the study.¹³¹⁴ While TP53 mutations are not themselves directly targetable with current drugs, they reflect the genomic instability of these tumors.

More immediately useful are the mutations and amplifications in genes that drugs already exist for. Across studies, about 20-30% of SDC tumors have ERBB2 (HER2) amplification, a similar fraction carry PIK3CA mutations, and roughly one in five have HRAS mutations.¹³¹⁴ Overall, one study found that nearly 80% of SDC tumors harbored at least one mutation that could theoretically be matched to an existing targeted therapy.¹³ That is an unusually high rate for a rare cancer and explains why molecular profiling is now considered essential for anyone diagnosed with SDC.

Surgery and Radiation as the Foundation

For SDC that has not spread to distant organs, surgery is the primary treatment. The operation aims to remove the entire tumor along with a margin of normal tissue. For parotid tumors, this typically means a parotidectomy, and for submandibular tumors, excision of that gland. When lymph nodes in the neck are involved, or when there is high suspicion they might be, a neck dissection is performed at the same time.

Because SDC is so aggressive locally, the vast majority of patients receive radiation after surgery. In one series, 89% of surgical patients went on to postoperative radiation, typically at doses around 60 Gy delivered over several weeks.¹⁵ Postoperative radiation reduces the chance of the cancer growing back at the original site. In one institutional review, local control at four years was 86% for patients treated with surgery followed by radiation.¹⁶ When the tumor has invaded along nerves (perineural invasion), radiation fields may be extended to cover the nerve pathways up to the base of the skull to chase any microscopic disease that tracked along those routes.¹⁷

The challenge is that even with excellent local control, SDC has a strong tendency to metastasize. In that same series with 86% local control, distant failure occurred in nearly half of patients within four years.¹⁶ Bone and lung are the most common destinations, each accounting for about 46% of distant metastases in a multicenter review, followed by the liver.¹⁸ This gap between controlling the tumor locally and preventing it from spreading distantly is the central problem in SDC treatment, and it is what has pushed researchers to borrow therapies from breast cancer.

Androgen Deprivation Therapy

Because most SDC tumors express androgen receptors at high levels, oncologists have adopted a strategy well-known in prostate cancer: blocking testosterone’s effect on the tumor. Combined androgen blockade, which uses medications to suppress testosterone production and block the androgen receptor simultaneously, has shown genuine activity in SDC. A prospective trial reported a response rate of about 42% and a clinical benefit rate of 75%, with a median time before the disease progressed of close to nine months.¹⁹ For a rare cancer that previously had almost no systemic options, those numbers were encouraging.

Androgen deprivation has also shown benefits in individual cases that were resistant to other approaches. One case report documented a patient with intracranial SDC metastases that had failed both radiation and HER2-targeted therapy but responded well to androgen-blocking treatment alone.²⁰ While case reports are not proof, they illustrate that androgen deprivation can sometimes work where other treatments do not.

There are limits, though. About half of SDC tumors carry a splice variant of the androgen receptor called AR-V7, which in prostate cancer is associated with resistance to hormonal therapies.¹² Whether AR-V7 predicts resistance to androgen blockade in SDC as reliably as it does in prostate cancer is an open question, but it is one reason researchers are investigating next-generation hormonal agents and combination strategies.

HER2-Targeted Therapy

Roughly 20 to 35% of SDC tumors overexpress HER2, the same protein that drives some aggressive breast cancers. In breast cancer, drugs like trastuzumab revolutionized outcomes, and the same drug has been applied to HER2-positive SDC. An early report of trastuzumab combined with chemotherapy found that all five patients with metastatic HER2-positive SDC responded, with one achieving a complete response lasting over four years.²¹ HER2-targeted therapy combined with chemotherapy (typically a taxane drug) is now considered the standard first-line approach for HER2-positive metastatic SDC.²²

A newer class of drugs called antibody-drug conjugates has extended this approach further. These drugs attach a chemotherapy payload directly to an antibody that targets HER2, delivering toxic treatment directly to cancer cells while sparing most normal tissue. Trastuzumab deruxtecan, which became a game-changer in breast cancer, has been studied in HER2-expressing salivary gland cancers. A pooled analysis of two phase I trials in salivary gland cancer patients reported a confirmed response rate of about 59%, with a median time before progression of over 20 months.²³ These results are remarkable for a cancer this aggressive and have made antibody-drug conjugates a promising option for patients whose disease progresses on standard trastuzumab combinations.²²

Chemotherapy and Immunotherapy

For patients whose tumors lack both HER2 overexpression and androgen receptor positivity, or for those who have progressed through targeted therapies, conventional chemotherapy remains an option. A systematic review of systemic treatments for recurrent or metastatic SDC found that the best-studied regimen is carboplatin combined with a taxane.²⁴ Response rates to chemotherapy alone tend to be modest, and responses are often short-lived, which is why targeted approaches are preferred when a tumor’s molecular profile allows it.

Immunotherapy with checkpoint inhibitors, which has transformed outcomes in many other cancers, has been explored in salivary gland cancers, but the evidence for SDC specifically remains thin. The same systematic review noted that evidence for immunotherapy in SDC is largely anecdotal.²⁴ Individual patients have responded, but there are not yet large enough trials to know who benefits and who does not. Research into liquid biopsy, which analyzes circulating tumor DNA and other markers from a blood draw, may eventually help match patients to immunotherapy or track treatment response without repeated imaging.²⁵

Prognosis and What Drives It

SDC carries a worse prognosis than most other salivary gland cancers. The majority of patients present with advanced disease: in one institutional series, over 80% had stage IV cancer at diagnosis.⁴ The high rate of distant metastasis is the primary driver of mortality. In a multicenter analysis, several features at diagnosis predicted higher chances of the cancer spreading: advanced nodal disease, stage IV classification, perineural invasion, and positive surgical margins all increased the risk substantially.¹⁸

One of those factors, positive margins, deserves emphasis because it is technically the most modifiable. When surgeons cannot achieve clear margins, the residual microscopic disease dramatically elevates the risk of both local recurrence and distant spread. This is why initial surgery by a surgeon experienced with salivary gland cancers is so important: a well-performed first operation gives the patient the best chance.

Living with Facial Nerve Consequences

Because the parotid gland is intimately wrapped around the facial nerve, treatment for parotid SDC often involves sacrifice of all or part of that nerve, either because the tumor has directly invaded it or because removing the tumor requires cutting through nerve branches. The resulting facial paralysis affects expression, eye closure, and eating. When nerve sacrifice is necessary, reconstruction or reanimation techniques can help restore tone and some movement to the face. The goal is to re-establish symmetry at rest and protect the eye from drying out due to an inability to blink fully.²⁶ Options range from nerve grafts performed at the time of tumor surgery to later procedures like muscle transfers. Planning for facial rehabilitation works best when it begins before surgery, not after.

Newer Targets on the Horizon

The molecular diversity of SDC means that the treatment landscape keeps expanding. For the small subset of patients whose tumors carry fusions involving the NTRK gene family, TRK inhibitors have shown striking activity in salivary gland cancers broadly, with response rates in the range of 86-90% in pooled analyses of phase I and II trials.²⁷ NTRK fusions are rare in SDC compared to some other salivary gland cancers, but when present, the response can be dramatic.

Beyond NTRK, antibody-drug conjugates targeting TROP2, a protein expressed on many salivary gland tumors, are in clinical trials. Early results from one TROP2-targeting conjugate showed a response in about a third of salivary gland cancer patients, including one complete response and evidence of activity against brain metastases.²⁸ ALK and BRAF alterations, though each found in only a handful of SDC cases, represent additional avenues where drugs already approved for other cancers could theoretically be repurposed.¹³ The overarching theme is that comprehensive genomic profiling of SDC tumors is no longer optional: it is the gateway to the most promising treatments currently available.

1
JAMA Otolaryngology–Head & Neck Surgery. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma
2
PubMed Central. Cystic Salivary Duct Carcinoma Penetrated by Facial Nerve
3
PubMed Central. Salivary duct carcinoma presenting with unilateral multiple cranial nerve lesions and concurrent intracranial metastasis: A case report
4
PubMed Central. Parotid salivary duct carcinoma: a single institution’s 20-year experience
5
PubMed. Environmental factors and the risk of salivary gland cancer
6
PubMed. Salivary duct carcinomas: clinical and CT and MR imaging features in 20 patients
7
PubMed. Salivary duct carcinoma: A report of 70 FNA cases and review of the literature
8
PubMed Central. Diagnostic and Prognostic Utility of 18F-FDG PET/CT in Recurrent Salivary Gland Cancers
9
PubMed Central. 68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study
10
Head and Neck Pathology. Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study
11
American Journal of Clinical Pathology. Homologous Carcinomas of the Breasts, Skin, and Salivary Glands
12
PubMed Central. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
13
PubMed Central. The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement
14
Modern Pathology. Molecular patterns in salivary duct carcinoma identify prognostic subgroups
15
PubMed. Salivary duct carcinoma: Treatment, outcomes, and patterns of failure
16
PubMed Central. Postoperative radiotherapy in salivary ductal carcinoma: a single institution experience
17
Journal of Radiation Research. Postoperative radiotherapy in patients with salivary duct carcinoma: clinical outcomes and prognostic factors
18
Advances in Radiation Oncology. Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience
19
PubMed Central. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma
20
PubMed Central. Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report
21
PubMed Central. Trastuzumab for the treatment of salivary duct carcinoma
22
Cancer Treatment Reviews. Salivary duct carcinoma: Symptoms, Diagnosis, & Treatment – Section: HER2-Targeted therapy
23
Japanese Journal of Clinical Oncology. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies
24
PubMed. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review
25
PubMed Central. Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers
26
PubMed. Management of the facial nerve in parotid cancer: preservation or resection and reconstruction
27
Japanese Journal of Clinical Oncology. Systemic therapy for salivary gland malignancy: current status and future perspectives
28
ESMO Rare Cancers. Precision oncology in salivary gland cancer: molecular landscape, therapeutic advances and emerging strategies